CA1078376A - Pentacyclic indolo-quinolizine derivatives - Google Patents

Pentacyclic indolo-quinolizine derivatives

Info

Publication number
CA1078376A
CA1078376A CA255,310A CA255310A CA1078376A CA 1078376 A CA1078376 A CA 1078376A CA 255310 A CA255310 A CA 255310A CA 1078376 A CA1078376 A CA 1078376A
Authority
CA
Canada
Prior art keywords
mls
adds
indolo
obtains
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA255,310A
Other languages
French (fr)
Inventor
Henri P. Husson
Pierre Potier
Claude Thal
Richard Besselievre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bpifrance Financement SA
Original Assignee
Agence National de Valorisation de la Recherche ANVAR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agence National de Valorisation de la Recherche ANVAR filed Critical Agence National de Valorisation de la Recherche ANVAR
Priority to CA255,310A priority Critical patent/CA1078376A/en
Application granted granted Critical
Publication of CA1078376A publication Critical patent/CA1078376A/en
Expired legal-status Critical Current

Links

Abstract

ABSTRACT OF THE DISCLOSURE

A pentacyclic derivative of the general formula:

I

in which:
R represents a hydrogen atom or a hydroxyethyl radical, R1 represents a hydrogen atom, R and R1 being in the trans position in relation to one another, or alternatively together forming a double bond, and R2 and R3, which may be the same or different, represent a hydrogen atom or a halogen atom or an alkyl radical containing 1 to 4 carbon atoms or alkyloxyl radical whose alkyl part contains 1 to 4 carbon atoms, or else R2 and R3 together form a dioxy-methylene radical, its optically active forms, its addition salts with acids, its quaternary ammonium salts and its N-oxides and the process for preparing said derivative.

Description

The present invention relates to a pen-tacyclic derivative of the general formula:

(I) O
~ .
in which:
R represents a hydrogen atom or a hydroxymethyl radical, Rl represents a hydrogen atom, -R and Rl being in the trans position in relation to one another, or alternatively together forming a double bond, and R2 and R3, which may be the same or different, represent a hydrogen atom or a halogen atom or an alkyl radical containing 1 to 4 carbon atoms or alkyloxyl radical whose alkyl part contains 1 to 4 carbon atoms, or else R2 and R3 to-- gether form a dioxymethylene radical, its optically active forms, its addition salts with acids, its quaternary ammonium salts and its N-oxides.
The novel products of the present inven-tion have noteworthy therapeutical properties, and are particularly interesting as cerebral protectors and vasodilators. The invention provides a pharma-; ceutical composition comprising the compounds of this invention.
In another aspect of this invention there is provided a process for the preparation of pent--- 30 acyclic derivatives of the general formula:

., ~ ` 1078376 , -R3 / ~ I

R

in which:
R represents a hydrogen atom or hydroxymethyl radical Rl represents a hydrogen atom;
R and Rl being in the trans position in relation to one another or alternatively together forming a double bond;
and R2 and R3, which may be the same or different, represent a hydrogen atom or a halogen atom or an alkyl radical containing 1 to 4 carbon atoms or alkloxyl radical whose alkyl part contains 1 to 4 carbon atoms or alternatively R2 and R3 together form a dioxmethylene radical, its optically active forms, its pharmaceuti- :
cally acceptable addition salts with acids, its pharmaceutically acceptable quaternary ammonium salts and its N-oxides;
which comprises reducing, in an acid medium an immonium salt of the general formula:

:i ~ ~ N + X II
0~
~:~ R

~ 2 :, ~

in which R, R2 and R3 are as defined above and X represents an anion from an organic or inorganic acid; -or which comprises deprotonising, in an alkaline medium, a pro-duct of the general formula X~ ' R3 ~ ~ + X II

~ O ;,, ' in which R2, R3 and X are as defined above, According to the present invention, the products of the general formula tI) in which R represents a hydrogen atom or a hydroxymethyl radical, the symbols R and Rl being in the trans position in relation to one another, and the symbols R2 and R3 are defined as above, may be obtained by the reduction in an ~: acid medium of an immonium salt of the general formula:

_ l ~ (II) .~
in which R, R2 and R3 are defined as above and X represents an anion such as the perchlorate ion (C104).
Generally, the reduction is carried outby meansof an alkali borohydride suchas sodiumborohydride at a pHin thevicinity - of 6 ina hydro-alcoholicmedium. It is notnecessary to isolate the product of the general formula (II) in order tocarry out thereduc-tion andit isparticularly advantageousto use the immoniumsalt of the generalformula (II) prepared in situ.
Other reducing agents are particularly suitable and among these one may mention: hydrogen in the presence of platinum ~ - 3 -1078376 ;

oxide or carbon containing palladium.
The immoniumsalt of the generalformula (II) may be obtain-ed by theaction of formaldehydeon anenamine ofthe generalformula:
2 - ~

R3 ~ N ~ N ~ (III) H

in which R2 and R3 are as defined above, followed by the salti-fication of the product obtained.
Generally speaking,the condensation of the formaldehyde with the enamineof the generalformula (III) is carried out in a hydro-alcoholic mediumsuch asa mixtureof water/ethanolat a tempera-ture of between20C andthe boiling pointof the reactionmixture.
The saltformation iscarried outby theaddition of an acidsuch as perchloric acid, to the reaction medium.
The condensation ofthe formaldehydewith theenamine ofthe general formula (III) may lead,according tothe relative proportions of formaldehyde andenamine, thetemperature andduration ofthe reac-tion, either toan immoniumsalt ofthe generalformula (II) in which' 20 R represents ahydrogen atom,or toan immoniumsalt ofthe general formula (II) in which Rrepresents a hydroxymethylradical, or to a mixture thereof. In the lattercase, the subsequent reduction leads to a mixture of products of the general formula (I), the ,, constituents of which may be isolated by the application of physicochemical methods such as fractional crystallisation or :;~
chromatography.

The immonium salt of the general formula (II) in which R represents a hydroxymethyl radical may also-be obtained by the action of formaldehyde on an immonium salt of the general formula (II) in which R represents a hydroqen atom.

~1 The enamine of the general formula (III) may be prepared by the deprotonation in an alkaline medium of an --immonium salt of the general formula: ~

. . .

X~3 (IV) H ~

in which R2 and R3 are as defined above and X represents an anion such as the perchlorate ion or the chloride ion.
The deprotonation is generally carried out by the addition of an aqueous solution of soda.
The immonium salt of the general formula (IV) may be obtained by the action of phosphorus oxychloride followed by the possible addition of an alkali perchlorate such as sodium perchlorate on to a derivative of a tryptamine of the general formula:

R

i "., ~' in which R2 and R3 are as defined above.

The cyclisation with phosphorus oxychloride is .:"
carried out in an organic solvent such as benzene, toluene, dichloroethane at a temperature between 20C and the reflux temperature of the reaction mixture.
The derivative of tryptamine of the general formula (V) may be obtained by one of the following methods:
1) by the action of ethyl 5-bromo valerianate on a tryptamine of the general formula:
~ 5 R3 ~ ~H2 (VI~

in which R2 and R3 are as defined above; ~-- 2) by the action of 1-(4,~-diethoxy-butyl)-2-piper-idone on a hydrazine of the general formula:
~, 2 ~
3 ~NH2 (VII) ' in which R2 and R3 are as defined above.
Generally one operates in the presence of zinc chloride at a temperature in the vicinity of 180C or in dilute hydrochloric acid at a temperature in the vicinity of 80C.
The 1-(4,4-diethoxy-butyl)-2-piperidone may be ~` obtained by the action of ethyl 5-bromo valerianate on 4,4-diethoxy butylamine.
The enamine of the general formula (III) may also be i prepared by the method of E. WENKERT and B. WICKBERG, J. Amer.
Chem. Soc., 84, 4914 (1962) and J. Amer. Chem. Soc., 87, 1580 ` (1965) or according to the method of R.N. SCHUT and T.J. LEIPZIG, J. Het. Chem., 43, 101 (1966) or G.C. MOINISSON, W. CETENKO, -J. SHAVEL, J. Org. Chem., 2771 (1964).
According to the invention, the products of the general formula (I) in which R and Rl together form a double bond may be obtained by the treatment in alkaline medium of an immonium salt of the general formula (II) in which R represents a hydrogen atom.
Generally speaking, th~ deprotonation is carried out by means of a mineral base such as soda.

The products of the general formula (I) may be separated into their optical isomers by the application of the usual methods. More particularly, one prepares an optically active salt of a product of the general formula (I) which is then separated by fractional crystallisation. The optically active base is regenerated from its salt by using the usual ;-methods. Preferably the splitting is carried out by means of optically active O,O'-di-paratoluoyltartaric acids.
The new products according to the invention may possibly be purified by physical methods (crystallisation, chromatography) or chemical methods (salt formation, crystallisation of the latter and then decomposition in an ~- -alkaline medium).
They may be converted if desired into addition salts with acids, into quaternary ammonium salts or into N-oxides.
The salts may be obtained by the action of the new derivatives on acids or reactive esters such as an alkyl halide in suitable solvents. As organic solvents one uses for example alcohols, ethers or chlorinated solvents. The salt formed is precipitated after the concentration of the solution and it is separated by filtration or decantation.
The new products according to the present invention and their salts present noteworthy therapeutical properties.
They are particularly interesting as cerebral protectors and vasodilators.
They have been found active in the animal at doses of between 0.1 and 5 mg/kg by intravenous route and at doses of between 5 and 50 mg/kg by oral route.
~ore particularly:
They increase significantly the survival time of mice placed in a confined atmosphere or at an imaginary altitude.

~C~78376 They reduce the time of reappearance of corticular electrogenesis in the rat subjected to a momentaneous cerebral hypoxia as a result of ischaemia.
and theY increase the femoral and coronary arterial output in the anaesthetised dog.
They also have a low toxicity. The 50~ lethal dose (DL50) is generally greater than 200 mg/kg by oral route in the mouse.
For medicinal use, the new compounds are used either 10 in the state of the base, or in the state of acceptable ~`~
pharmaceutical salts, that is to say ones which are non-toxic at the doses at which they are used.
The following examples, which are given without being .restrictive, show how the invention may be put into practice.
'~jIn the following, the structure of the products and in particular that of 1,12b trans-1,2,3,4,6,7,12,12b-octahydro-1,1-methanooxymethano(2,3-a) indoloquinolizine, was determined by X-ray analysis and the structure of the other products for which R and Rl each represent a hydrogen atom, was confirmed by ~20 the comparison of the spectral data.
., .:, ~ .

1 g of 2,3,4,6,7,12-hexahydro-(2,3-a) indoloquinolizine is dissolved in 50 mls of ethanol and then one adds 5 mls of a 40% aqueous solution of formaldehyde.
The reaction medium is heated with agitation for 10 minutes at 70C. One adds 2 mls of perchloric acid and then one adds, in small portions, 2 g of sodium borohydride over 30 minutes.
After the addition of 200 mls of water saturated with sodium chloride, one extracts with 200 mls of chloroform. After drying the organic solution over sodium sulphate and evaporating the solvent, one isolates a residue which is filtered in chloroform solution over a column of 80 g of silica.
The elution of the first chloroform fractions (approximately 1 litre) supplies 1.1 g of 1,12b-trans-1,2,3,4,-
4,7,12,12b-octahydro-1,12-methanooxymethano-(2,3-a)-indolo-quinolizine which, after crystallisation from ethyl acetate mels at 150C and also possesses the following properties:
Infra-red spectrum: (determination in solution in chloroform).
Bands at 2860-28Q0 and 2755 cm 1 characterising the trans-quinolizidine chain (Bohlmann's bands).
Mass spectrum: peaks at m/e 268 (M 100%), 267, 237.
NMR spectrum: (CDC13):
4H aromatics between 7.6 and 6.9 ppm; 2H (Na-CH2-O):
` 2 doublets centred at 5.7~ and 4.85 ppm JAB = 12Hz; 2H (OCH2-C_):
.1 2 quadruplets centred at 3.92 and 3.3 ppm (JAB = 12Hz, JAX = 4Hz, BX lOHz).
, The corresponding tartrate is prepared by dissolving 1.1 g of the above base in 40 mls of methanol and then adding 0.3 g of tartaric acid dissolved in 30 mls of methanol. After concentrating the methanol the salt is precipitated; it is dried and one obtains 1.1 g of 1,12b-trans-1,2,3,4,6,7,12,12b-octa-hydro-1,12-methanooxymethano-(2,3-a)-indolo-quinolizine tartrate melting at 222C (yield: 79%).

To a solution of 0.1 g of 2,3,4,6,7,12-hexahydro(2,3-a)-indoloquinolizine in 20 mls of ethanol one adds 2 mls of a 40 aqueous solution of formaldehyde.

The reaction mixture is heated, with agitation, at _ 9 _ ~078376 60C for 15 minutes. After concentrating the hydroalcoholic solution one adds 0.1 ml of perchloric acid. The precipitate which is formed is filtered and then washed with water. In this way one obtains 85 mg of perchlorate which, after alkalisation by a drop of concentrated soda provides 35 mg of 1,12-methano-oxymethano-2,3,4,6,7,12-hexahydro(2,3-a) indoloquinolizine which possesses the following characteristics: `
Mass spectrum: Peaks m/e : 266 (M 100~
NMR spectrum (CDC13): 4H aromatics between 7.6 and 6.9 ppm;
2H (Na-CH2-O):
1 singlet at 5.8 ppm; 2H(O-CH2): 1 singlet widened at 4.45 ppm.

a) To 1 g of 1,2,3,4,6,7,12H-hexahydro-(2,3-a)-indolo-quinoli-zinium perchlorate dissolved in 100 mls of ethanol one adds ' 0.3 g of sodium carbonate and then 25 mls of a 40% aqueous solution of formaldehyde. The reaction mixture is heated for 30 minutes at 60 C. One then adds, after cooling, 200 mls of water and then one extracts with 200 mls of chloroform.
After drying the chloroform solution over sodium sulphate and evaporating the solvent, the residue is dissolved in 100 mls of methanol. One adds over a period of 10 minutes 1 g of sodium borohydride. The state of advancement of the reaction is followed by thin layer chromatography. After the usual treatment one obtains 0.45 g of 1-hydroxymethyl-1,2,3,4,-6,7,12,12b octahydro-1,12 methanooxymethano-(2,3-a) indolo-quinolizine which melts at 148C and has the following physical properties:
Mass spectrum: peaks at m/e : 298 (M 100%).

NMR spectrum (CDCl ): 4E~ aromatics between 7.55 and 7 ppm;

- ~078376 2H (Na-CH20) : 2 doublets centred at 5.88 and 4.99 ppm (JAB =
12HZ) ; 4H (-O-CH2-C-CH2-OH) : massif centred at 3.6 ppm.

b) The hydrochloride is obtained by dissolving the above ~ r compound in the minimum of methanol and adding a few drops of concentrated hydrochloric acid (12N).
; The hydrochloride obtained is recrystallised from a mixture of ethyl acetate/methanol (50/50) and melts at 218-219C.

c) l-hydroxymethyl-1,2,3,4,6,7,12,12b octahydro-1,12 methano-oxymethano-(2,3-a) indolo-quinolizine may also be obtained from 2,3,4,6,7,12 hexahydro-(2,3-a) indolo-quinolizine :
- To 1 g of 2,3,4,6,7,12 hexahydro-(2,3-a) indolo-quinolizine dissolved in 1 ml of ethanol one adds 40 mls of a 40% aqueous solution of formaldehyde. It is agitated for 30 minutes at a temperature of 60C. It is diluted with 50 mls of methanol and then reduced with 6 g of sodium borohydride. One adds 200 mls of a saturated aqueous solution of sodium chloride and then extracts twice with 200 mls of chloroform.
After the usual treatment one obtains 0.3 g of l-hydroxymethyl-1,2,3,4,6,7,12,12b-octahydro-1,12 methanooxy-methano-(2,3-a) indolo-quinolizine which is identical to the product obtained in Example 3a.

One heats to 60C a solution of 4.6 g of 10-methoxy-2,3,4,6,7,12-hexahydro-(2,3-a) indolo-quinolizine in 460 mls of ethanol and then one adds over a period of 1 minute under an atmosphere of nitrogen 9 mls of a 30~ aqueous solution of formaldehyde. It is left for exactly 10 minutes in contact at 65C, and then one adds 2.39 mls of 70~ perchloric acid and it is cooled to 20C in a bath of iced water. One then adds in :1078376 small portions 3.15 g of sodium borohydride and it is left with agitation for 45 minutes. After diluting with 180 mls of a saturated solution of sodium chloride and 800 mls of water, one ; extracts three times with 250 mls of dichloromethane, the organic ~' . phase is washed twice with 100 mls of water, dried over sodium sulphate, filtered and concentrated to dryness under reduced pressure (20 mm of mercury) at 20C. The residue is taken up in three times 200 mls of boiling isopropyl oxide; the solution obtained after elimination of a brown residue by filtration is concentrated to a volume of 150 mls. After cooling for 1 hour to +4C the crystals are filtered and dried under reduced ;~ pressure (20 mm of mercury) at 20C. In this way one obtains 3.5 g of 1,12b trans-10-methoxy-1,2,3,4,6,7,12,12b-octahydro-1,12 methanooxymethano- (2,3-a) indolo-quinolizine melting at 136C.
After recrystallisation from a mixture of acetone and `
water (1/2 by volume), the product melts at 1~0C, Analysis % Calc.: C 72.46 H 7.43 N 9.39 O 10.72 Found: 71.6 7.25 9.15 11.5 10-methoxy-2,3,4,6,7,12-hexahydro-(2,3-a) indolo-quinolizine may be prepared in the following manner:
To a solution of 5.44 g of 1-~ (6-methoxy-3-indolyl) ethy~ -2-piperidone in 300 mls of 1,2-dichloroethane one adds, under an atmosphere of nitrogen and accompanied by agitation, over a period of 10 minutes 5 mls of phosphorus oxychloride. It is then heated under reflux for 3 hours and then allowed to return to a temperature of 50C. One then adds 150 mls of distilled water and heats it again under reflux for 45 minutes.
After cooling to 50C, the reaction mixture is decanted. The organic phase is extracted with twice 20 mls of water at approximately 50 C. To the aqueous phase one adds 6 g of sodium ~ o7s376 perchlorate.
After cooling for 1 hour to 4C, the precipitate is separated by filtration and then dried under reduced pressure (0.5 mm of mercury), at 20C.
In this way one obtains 6.5 g of 10-methoxy-1~2,3,4,6,~
7,12H-hexahydro-(2,3-a)-indolo-quinolizinium perchlorate in the form of a light green crystalline solid.
This product is dissolved in 400 mls of boiling methanol. One adds 400 mls of distilled water and leaves it to cool to 20C. One then adds drop by drop, accompanied by agitation, 2 mls of 10N soda so as to obtain a pH in the vicinity of 10. The mixture is cooled in an ice bath. After cooling for 1 hour, the product obtained is separated by filtration and then dried under reduced pressure (0.55 mm of mercury) at 20C. In this way one obtains 4.6 g of 10-methoxy-2,3,4,6,7,12-hexahydro-(2,3-a)-indolo-quinolizine melting at 166C.
1-[2(6-methoxy-3-indolyl)-ethy~ -2-piperidone may be prepared in the following manner:
One heats under a reflux, under an atmosphere of 20 nitro~en, a suspension of 9.5 g of 6-methoxy tryptamine and 5.32 g of sodium carbonate in 124 mls of methoxyethanol and then one adds over a period of 30 hours accompanied by agitation a solution of 10.4 g of ethyl bromovalerianate in 82 mls of methoxyethanol. The agitation and the reflux are continued for 1 hour and 30 minutes after the end of the addition and the mixture is concentrated under reduced pressure (0.5 mm of mercury) down to a volume of 50 mls. After dilution with 500 mls of distilled water, one extracts with three times 200 mls of dichloromethane. The organic phase is washed with two times 100 mls of a normal solution by hydrochloric acid and two times 100 mls of a saturated solution of sodium chloride. After drying ~' over magnesium sulphate, treatment with animal charcoal and filtration, it is concentrated to dryness under reduced pressure (20 mm of mercury) at 20C. One obtains in this way 11.2 g of a light yellow solid which is purified by chromato-graphy on a column of 150 g of silica gel (neutral p~ 0.05-0.2) contained in a column 1.6 cm in diameter. It is eluted successively with 300 mls of a mixture of cyclohexane/ethyl acetate (50:50 by volume), 300 mls of a mixture of cyclohexane/
10 ethyl acetate (25:75 by volume), 600 mls of ethyl acetate and 1200 mls of a mixture of ethyl acetate/methanol (98:2 by volume), collecting fractions of 100 mls. Fractions 7 to 25 are combined and concentrated to dryness under reduced pressure (20 mm of mercury) at 20C. One obtains in this way 7.5 g of l-C2(6-methoxy-3-indolyl)ethyl~-2-piperidone melting at 146C.
6-methoxytryptamine may be prepared according to N.N. SUVOROV and co-workers, Zh. Obshch. Khim., 30, No. 9, 3118 (1960).

One dissolves 18.5 g of 10-fluoro-2,3,4,6,7,12-hexa-hydro-(2,3-a)-indolo-quinolizine in 2 litres of ethanol at 60C. One adds in one go 49.2 mls of formaldehyde in a 30%
aqueous solution. The reaction mixture is agitated for 10 minutes at 60C. One adds 12.9 mls of 65% perchloric acid and the reaction mixture is cooled to 20C. One then adds 15.9 g of sodium ~orohydride and it is left with agitation for 1 hour and 20 minutes. One then pours the reaction mixture into 800 mls of a saturated aqueous solution of sodium chloride. It is agitated for 45 minutes with 800 mls of methylene chloride and then the organic phase is separated. The aqueous phase is 1078376 ~ ~

extracted three times with 800 mls of methylene chloride. The organic extracts are combined, washed with 500 mls of distilled water and dried over sodium sulphate in the presence of 5 g of bleaching carbon. After filtration and concentration to dryness under reduced pressure (20 mm of mercury~ one obtains 21.2 g of a residue which is dissolved in 80 mls of methylene chloride and filtered over 70 g of silica contained in a column 2.5 cm in diameter. The silica is washed with 1.7 litres of methylene chloride. The methylene chloride is concentrated under reduced pressure (20 m~ of mercury): one obtains 15.9 g of a crystalline residue which is purified by recrystallisation from 930 mls of isopropyl oxide. One obtains in this way 8.5 g of 1,12b-trans-l-fluoro-1,2,4,6,7,12,12b-octahydro-1,12-methanoxymethano-(2,3-a)-indolo-quinolizine melting at 158-159 C.
Analysis Calculated % C 71.31 H 6.69 F 6.63 N 9.78 Found: 71.40 6.65 6.75 9.60 10-fluoro-2,3,4,6,7,12-hexahydro-(2,3-a)-indolo-quinolizine may be prepared in the following manner:
To a suspension of 24 g of 1- [2(6-fluoro-3-indolyl)-ethyl~-piperidone in 1 litre of toluene one adds over a period of 30 minutes 24 mls of phosphorus oxychloride dissolved in 100 mls of toluenen It is then heated to 80C for 3 hours. It is then left to cool and one adds, accompanied by agitation, 550 mls of distilled water. It is heated again to 80C for 45 minutes. It is allowed to cool to 50C and the aqueous phase is separated by decantation. One extracts the organic phase with twice 100 mls of water. One adds, accompanied by agitation, 24 g of sodium perchlorate dissolved in 240 mls of distilled water, to the combined aqueous extracts. A product is precipitated. After 1 hour and a half of cooling to 4C, the crystals are separated by filtration. In this way one obtains 30.4 g of 10-fluoro-1,2,3,4,6,7,12H-hexahydro-(2,3-a)-indolo~
- quinolizinium perchlorate melting at 223C.
30.3 g of the perchlorate thus obtained is dissolved in 2.1 litres of boiling methanol and then one adds 2.1 litres , .
of distilled water and one cools to a temperature in the vicinity of 20C. One then adds 100 mls of normal soda. A product is precipitated, which is separated by filtration, washed with 500 mls of distilled water.
In this way one obtains 17.2 g of 10-fluoro-2,3,4,6,7,-12-hexahydro-~2,3-a)-indolo-quinolizine melting at 134 C.
l-t2(6-fluoro-3-indolyl)ethy~ piperidone may be prepared in the following manner:
To 22.7 g of 6-fluoro tryptamine dissolved in 600 mls of methoxyethanol one adds 13.3 g of anhydrous sodium carbonate and one heats under reflux under an atmosphere of nitrogen.
One adds, over a period of 3 days, 26.5 g of ethyl 5-bromo valerianate in 50 mls of methoxyethanol. The reflux is continued : i for 5 hours. After the end of the addition one concentrates to .
dryness under reduced pressure (20 mm of mercury). The residue ; is taken up in 300 mls of water. It is extracted 4 times with 450 mls of methylene chloride. The organic extracts are combined and are washed with 100 mls of N hydrochloric acid and then with twice 100 mls of water, dried over sodium sulphate in the presence of 0.2 g of bleaching carbon. After filtration and concentration to dryness under reduced pressure (20 mm of mercury), one obtains 27.7 g of a crystalline residue which is purified by chromatography over 125 g of silica contained in a column with a diameter of 3 cm, by eluting with 3.5 litres of ethyl acetate. After the concentration of the eluates one ~078376 .
obtains 24 g of 1- L2(6-fluoro-3-indolyl)ethy~ piperidone melting at 146C. 6-fluoro tryptamine may be prepared according to the process described in British Patent 846.675.

One heats to 60 C a suspension of 8.6 g of 9-methyl-2,3,4,6,7,12-hexahydro-(2,3-a)-indolo-quinolizine in 750 mls of ethanol. One obtains a solution to which one adds, over a period of 2 minutes, 20.6 mls of a 30% aqueous solution of formaldehyde. The reaction mixture is maintained at 60C for 10 minutes. One adds 5.4 mls of 70% perchloric acid over a period of 1 minute and the reaction medium is then cooled to 20C. One then adds in small portions and accompanied with -~
agitation 7.1 g of sodium borohydride over a period of 15 minutes, it is allowed to continue with agitation for a further 30 minutes and then the mixture is poured into 375 mls of a saturated solution of sodium chloride, it is left for 5 minutes with agitation and extracted twice with 400 mls of chloroform.
The organic phase is dried, filtered over bleaching carbon and evaporated to dryness under reduced pressure (20 mm of mercury).
In this way one obtains 9.8 g of crude product which is chromatographed over 500 g of basic alumina contained in a column with a diameter of 43 cm, eluting with methylene chloride and collecting fractions of 120 mls. Fractions 2 to 14, after concentration, provide 5 g of a product which is recrystallised from 50 mls of acetone. One obtains in this way 3.3 g of 1,12b-trans-9-methyl-1,2,3,4,6,7,12,12b-octahydro-1,12-methan~-~! oxymethano-(2,3-a)-indolo-quinolizine, melting at 183C.

Analysis: Calculated % C 76.56 H 7.85 N 9.92 Found 76.5 7.6 9.7 9-methyl-2,3,4,6,7,12-hexahydro-(2,3-a)-indolo-quinolizine may be prepared in the following manner:

To a solution of 16 g of 1- C2t5-methyl- 3-indolyl)-ethyl~-2-piperidone in 450 mls of toluene one adds 15 mls of phosphorus oxychloride and heats the mixture at 85 C for 3 hours.
It is cooled to 20C and then one adds 200 mls of water and heats it again to 90 C for 40 minutes accompanied by agitation.
The mixture is cooled. ~fter decantation, the organic phase is washed with 200 mls of water. The aqueous phases are combined and heated to 40C. One then adds over a period of 3 minutes a solution of 15 g of sodium perchlorate in 100 mls of water. An oil is salted out. After cooling, the water is decanted; one adds 500 mls of water to the residue and hçats under a reflux. After cooling, the crystallised yellow product is separated by filtration and dried. One obtains in this way 13.1 g of 9-methyl-1,2,3,4,6,7,12H-hexahydro-(2,3-a)indolo-quinolizinium perchlorate in the form of yellow crystals.
This perchlorate obtained in this way is dissolved at 50C in a mixture of 750 mls of water and 750 mls of methanol and one adds 4~1 soda to it to bring the pH to 20. An emulsion is formed which crystallises when cooled. After leaving it for 20 1 hour at 5C, it is filtered. One obtains in this way 8.6 g !~
of 9-methyl-2,3,4,6,7,12 hexahydro-(2,3-a)indolo-quinolizine melting at 167C.
2(5-methyl-3-indolyl)-ethyl~ -2-piperidone may be prepared in the following manner:
To a suspension of 14 g of 5-methyl tryptamine hydrochloride and 7.2 g of sodium carbonate in 250 mls of methoxyethanol heated under a reflux, one adds over a period of 8 hours a solution of 15 g of ethyl 5-bromo valerianate in 45 mls of methoxyethanol. The heating under a reflux is maintained for a further 16 hours. After cooling, the mineral salts in suspension are separated by filtration and the filtrate is evaporated to dryness under reduced pressure (20 mm of mercury).
The residue is taken up in a mixture of 250 mls of water and 500 mls of methylene chloride. After decanting, the aqueous phase is extracted again with 250 mls of methylene chloride.
The combined organic phases are washed 3 times with 500 mls of dilute hydrochloric acid, dried over sodium sulphate, filtered over bleaching carbon and evaporated to dryness under reduced pressure. In this way one obtains 16 g of 1- [2(5-methyl-3-indolyl) ethy~-2-piperidone in a form which can be used without subsequent purification.
5-methyl tryptamine hydrochloride may be prepared according to M. PROTIVA and co-workers, Czech. Chem. Comm., 25, 784 (1960).

One heats to 60C a solution of 8.4 g of 9-methoxy-2,3,4,6,7,12-hexahydro(2,3-a) indolo-quinolizine in 840 mls of ethanol and one rapidly adds 22.2 mls of a 30% aqueous solution of formaldehyde. The temperature is maintained for 10 minutes at 60C and then one rapidly adds 5.6 mls of 70% perchloric acid. The reaction medium is cooled to 20C and becomes heterogeneous. One adds in small portions over a period of 4 minutes 7.20 g of sodium borohydride and then one leaves it for 45 minutes with agitation, one adds 300 mls of a saturated solution of sodium chloride and agitates for 10 minutes. One then adds 1000 mls of water and 1000 mls-of methylene chloride and continues the agitation for a further 10 minutes. After decanting, the aqueous phase is extracted again with 1000 mls of methylene chloride. These organic phases are combined, washed with 500 mls of water and 750 mls of a saturated solution of sodium bicarbonate and dried over sodium sulphate, filtered over bleaching charcoal. In this way one obtains, after evaporation to dryness under reduced pressure (20 mm of mercury) 11 g of crude product which is chromatographed over 200 g of basic alumina contained in a column with a diameter of 30 cm, eluting with methylene chloride and collecting fractions of 60 mls. Fractions 2 to 24 after concentration provide 7.7 g of a product which is recrystallised from 150 mls of a mixture of ethyl acetate and isopropyl oxide (1:1 by volume). One obtains -in this way 5 g of 1,12b-trans-9-methoxy-1,2,3,4,6,7,12,12b octahydro-1,12 methanoxymethano(2,3-a) indolo-quinolizine melting at 130C.
Analysis Calculated: C 72.46 H 7.43 N 9.39 Found: 72.4 7.4 9.2 9-methoxy-2,3,4,6,7,12-hexahydro (2,3-a) indolo-quinolizine may be prepared in the following manner:
To a suspension of 17 g of 1- C2(9-methoxy-3-indolyl) - ' ethy~-2-piperidone in 500 mls of toluene one adds over a period of 2 minutes 17.2 mls of phosphorus oxychloride and then one heats to 80C for 3 hours accompanied by agitation. It is cooled to 50C and then one adds 400 mls of water and heats the mixture again to 85C for 30 minutes. After cooling, one adds 1000 mls of water, decants and eliminates the organic phase.
To the aqueous phase, heated to 50C, one adds a solution of 17 g of sodium perchlorate in 180 mls of water. A precipitate ; is formed which, after cooling to 20C, is separated by filtration. In this way one obtains 18 g of 1,2,3,4,6,7,12H
hexahydro-(2,3-a) indolo quinolizinium perchlorate in the form of pale yellow crystals. One dissolves 16.5 g of the perchlorate so obtained in a mixture of 1300 mls of methanol and 1500 mls .

of water at 55C. It is cooled to 40C and one adds over a period of 10 minutes 100 mls of 4N soda. After 30 minutes of cooling to 10C, the crystals obtained are separated by filtra-tion. One obtains in this way 8.5 g of 9-methoxy-2,3,4,6,7,12-hexahydro (2,3-a) indolo-quinolizine in the form of yellow crystals melting at about 130C.
l-C2(5-methoxy-3-indolyl)-ethyl~-2-piperidone may be prepared in the following manner:
One heats to 80C a solution consisting of 140 mls of water, 60 mls of acetic acid and 40 mls of normal hydrochloric acid. One then adds 5.52 g of p-methoxyphenylhydrazine followed by 9.7 g of 1-(4,4-diethoxybutyl)-2-piperidone. The solution is maintained at 80C for 2 hours. It is then cooled to 5 C
and then one adds 200 mls of water and 150 mls of methylene chloride. After decanting, the aqueous phase is extracted again with 200 mls of methylene chloride. The organic phases are combined, washed with 100 mls of water and then with a saturated solution of sodium bicarbonate, dried over sodium sulphate, filtered over bleaching charcoal and then evaporated to dryness under reduced pressure (20 mm of mercury). The residue (10 g) is chromatographed over 75 g of silica gel contained in a column with a diameter of 2.7 cm and eluting with ethyl acetate, collecting fractions of 120 mls. Fractions 4 to 12 are evaporated. In this way one obtains 7.5 g of 1- ~1(5-methoxy-3-, indolyl)-ethy~-2-piperidone melting at 150 C.
1-(4,4-diethoxy-butyl)-2-piperidone may be prepared in the following manner:
To a solution of 97 g of 4,4-diethoxybutylamine in 1800 mls of methoxy-ethanol heated under a reflux one adds over a period of 19 hours a solution of 130 g of ethyl 5-bromo , valerianate in 160 mls of methoxyethanol. The mixture is heated under a reflux for a further hour after the end of the addition.
After cooling, the mineral salts are separated by filtration and the filtrate is evaporated to dryness under reduced pressure (20 mm of mercury). The residue is dissolved in 1000 mls of methylene chloride, washed twice with 500 mls of water and then with 500 mls of a 4% solution of citric acid. The organic phase is dried over sodium sulphate, filtered over bleaching charcoal and evaporated to dryness. In this way one obtains 122.5 g of crude 1-(4,4-diethoxy-butyl)-2-piperidone which is used without subsequent purification.

To a solution of 17.5 g of 9-chloro-2,3,4,6,7,12- ; !
hexahydro(2,3-a)-indolo-quinolizine in 1700 mls of ethanol at 60C one rapidly adds 45.4 mls of a 30% aqueous solution of formaldehyde. It is maintained at 60C for 10 minutes and then one rapidly adds 11.5 mls of 70% perchloric acid. After cooling the mixture to 20~, one adds, over a period of 3 minutes in small portions, 14.7 g of sodium borohydride accompanied by agitation. The agitation is continued for a further 30 minutes and then one adds 350 mls of a saturated solution of sodium chloride and 500 mls of water. The agitation is continued for a further 20 minutes and then it is extracted with 800 mls of methylene chloride. The organic layer is washed with 1000 mls of water, dried over sodium sulphate, filtered over bleaching charcoal and evaporated to dryness. One obtains 20 g of a crude product which is recrystallised from 150 mls of ethyl acetate.
One obtains in this way 11 g of 1,12b trans-9-chloro-1,2,3,4,6,- -7,12,12b octahydro-1,12 methanoxymethano-2,3-a) indolo-quino-lizine in the form of white crystals melting at 154C.

~078376 Analysis Calculated % C 67.43 H 6.33 Cl 11.71 N 9.25 Found 67.6 6.3 11.8 9.0 9-chloro-2,3,4,6,7,12 hexahydro (2,3-a) indolo-quinolizine may be prepared in the following manner:
To a suspension of 1~.5 g of 1- ~2(5-chloro-3-indolyl)-ethyl~-2-piperidone in 375 mls of toluene one adds 16.5 mls of phosphorus oxychlori~e and then one heats this mixture for 3 hours at 80C. After cooling to 30C one adds 750 mls of water and then one heats again at 85C for one hour. After cooling and decanting, the organic phase is extracted with 100 mls of water. The aqueous phases are combined and heated to 55C, one then adds a solution of 16.5 g of sodium perchlorate in 180 mls of water. The suspension formed is cooled to 15C and then filtered. One obtains in this way 21g of 9-chloro-1,2,3,4,6,7,-12-H hexahydro(2,3-a) indolo-quinolizinium perchlorate in the form of orange crystals melting at about 300C with decomposi-tion.
One dissolves 28 g of the perchlorate thus obtained in a mixture brought to reflux of 850 mls of methanol and 500 mls ~,20 of water. One then adds 35 mls of 4N soda whilst slowly cooling to 5C. The crystals formed are separated by filtration and ~`
dried. One obtains in this way 17.5 g of 9-chloro-2,3,4,6,7,12 hexahydro(2,3-a) indolo-quinolizine in the form of yellow crystals melting at 147C.
l- [2(5-chloro-3-indolyl ethy~ -2-piperidone may be prepared in the following manner:
One gradually heats a mixture of 31 g of anhydrous zinc chloride, 31 g of p-chlorophenylhydrazine and 52.5 g of l-(4,4-diethoxy-butyl)-2-piperidone to 115C. The ethanol formed is eliminated by distillation. One continues heating, and at 170C an exothermic reaction is formed which brings the mixture to 240C. The mixture is then maintained at 180C for 4 hours.
After cooling the mixture, one adds 150 mls of a 2N
solution of acetic acid and then heats under a reflux for 5 minutes. After cooling, one adds 150 mls of methylene chloride.
After decanting, the aqueous phase is extracted again with 200 mls of methylene chloride. The organic phases are combined, washed with 200 mls of water, 300 mls of a saturated solution ~ -of sodium bicarbonate, dried over sodium sulphate and evaporated to dryness under reduced pressure (20 mm of mercury). The residue (56 g) is chromatographed over 500 g of silica gel contained in a column 5 cm in diameter and eluting with ethyl acetate, collecting fractions of 400 mls. Fractions 8 to 15 are evaporated to dryness. One obtains in this way 32 g of l-C2(5-chloro-3-indolyl) ethyl~-2-piperidone, melting at 158C.

; To a solution heated to 60C of 19 g of 9-fluoro-2,3,4,6,7,12 hexahydro-(2,3-a) indolo-quinolizine in 1900 mls of ethanol one adds, over a period of 1 minute, 40.5 mls of a 30%
aqueous solution of formaldehyde. It is left at 60 for 10 minutes whilst agitating and then one adds, over a period of 1 minute, 10.8 mls of a 70% perchloric acid solution. It is cooled to 20 and then one adds in small fractions 14.3 g of sodium borohydride, and it is then left for a further 30 minutes accompanied by agitation. One then adds 600 mls of a saturated solution of sodium chloride and then extracts it with twice 1000 mls of chloroform. The combined extracts are washed with 1000 mls of water, dried over sodium sulphate, filtered and evaporated to dryness under reduced pressure (20 mm of mercury).

, . ..

The residue (22.5 g) is recrystallised twice from acetone. One obtains in this way 7.3 g of 1,12b-trans-9-fluoro-1,2,3,4,6,7,-12,12b octahydro-1,12 rnethanoxymethano-(2,3-a) indolo-quinolizine in the form of pale yellow crystals melting at about 155 C.
Analysis Calculated ~ C 71.31 H 6.69 F 6.63 N 9.78 Found 70.3 6.5 6.9 9.8 9-fluoro-2,3,4,6,7,12-hexahydro (2,3-a) indolo-quinolizine may be prepared in the following manner:
To a suspension of 30 g of 1- ~2(5-fluoro-3-indolyl) ethy~-2-piperidone in 1500 mls of toluene, one adds 28 mls of phosphorus oxychloride and heats to 80C, accompanied by agitation, for 3 hours. It is then cooled to about 50C and then one adds 750 mls of water and heats to 85C for 45 minutes.
After cooling and decanting, the organic phase is extracted twice with 100 mls of water, the aqueous phases are combined and heated to 50C. One then adds a hot solution of 30 g of sodium perchlorate in 200 mls of water. A precipitate is formed.
The suspension is agitated for 30 minutes in an ice bath. The precipitate is separated by filtration. In this way one obtains 40 g of 9-fluoro-1,2,3,4,6,7,12-H hexahydro(2,3-a) indolo-quinolizinium perchlorate in the form of orange crystals.
This perchlorate is dissolved at 20C in a mixture of 2500 mls of methanol and 2500 mls of water. One adds, with agitation, to this solution 10N soda so as to bring the pH to 10. A precipitate is formed. The mixture is agitated for 30 minutes in an ice bath. The precipitate is separated by filtration and dried and one obtains in this way 19 g of 9-fluoro-2,3,4,6,7,12-hexahydro(2,3-a) indolo-quinolizine in the form of orange crystals melting at about 108C.
1- ~2(5-fluoro-3-indolyl) ethy~-2-piperidone can be prepared in the following manner:

~078376 One gradually heats a mixture of 16.3 g of anhydrous zinc chloride, 14.5 g of p-fluorophenylhydrazine and 28 g of 1-(4,4-diethoxy-butyl)-2-piperidone. At 110C one eliminates by distillation the ethanol formed and then one continues to heat.
From 150C, an exothermic reaction is produced and the tempera-ture of the reaction mixture rises to a temperature of 210C.
The temperature is then maintained at 180C for 4 hours. After cooling to about 100C, it is extracted twice under a reflux with 100 mls of a water/ethanol mixture (1:1 by volume). To these extracts one adds 10 mls of acetic acid and then one extracts three times with 200 mls of methylene chloride. The combined organic extracts are washed with 200 mls of a saturated solution of sodium bicarbonate, dried over sodium sulphate, filtered over a bleaching charcoal and evaporated to dryness, (20 mm of mercury). One obtains 38 g of a brown gum which is chromatographed over 500 g of silica gel contained in a column with a diameter of 5 cm, collecting fractions of 500 mls and eluting with ethyl acetate. Fractions 20 to 36 are combined :.
and evaporated to dryness. In this way one obtains 22 g of 1- ~2(5-fluoro-3-indolyl) ethyl~ -2-piperidone in the form of pale yellow crystals melting at 152C.

One heats to 65C under an atmosphere of nitrogen a solution of 17.8 g of 9,10-dioxymethylene-2,3,4,6,7,12 hexahydro (2,3-a) indolo-quinolizine in 1700 mls of ethanol, and then in a period of 1 minute one adds 37.6 mls of a 30% aqueous solution of formaldehyde. A precipitate is formed. It is maintained at 65C for 10 minutes and then in a period of 1 minute one adds 9.9 mls of 70% perchloric acid and then leaves it to cool with agitation to 25C. One then adds over a period of 15 minutes, - , ,, ~

in small portions, 13.2 g of sodium borohydride and then continues the agitation for 30 minutes. One adds to the mixture 700 mls of a saturated solution of sodium chloride, ~-1000 mls of chloroform and 400 mls of water. After decanting, the aqueous phase is extracted again with 600 mls of chloroform.
The organic fractions are combined, washed twice with 1500 mls of water, dried over sodium sulphate and concentrated to dryness.
The residue (16.8 g) is chromatographed over 400 g of silica gel contained in a column with a diameter of 5 cm, collecting 10 fractions of 600 mls and eluting with a mixture of methylene ~`
chloride/ethyl acetate (85:15 by volume). Fractions 5 to 15 are combined and evaporated. The residue, ~.9 g, is recrystallised successively from a mixture of ethyl acetate and acetone. In this way one obtains 3.5 g of 1,12b-trans-9,10-methylenedioxy-1,12-methanoxymethano-1,2,3,4,6,7,12,12b octahydro(2,3-a) indolo-quinolizine in the form of white crystals melting at 234C.
Analysis Calculated % C 69.21 H 6.45 N 8.97 O 15.37 Found 69.4 6.5 8.8 15.3 9,10-methylenedioxy-2,3,4,6,7,12-hexahydro(2,3-a) indolo-quinolizine may be prepared in the following manner:
One heats under a reflux under an atmosphere of ' nitrogen a solution of 10.25 g of C2(5,6-methylenedioxy-3-indolyl) ! ethylJ-2-piperidone in 475 mls of 1,2-dichloroethane and one adds over a period of 10 minutes a solution of 10.5 mls of ~ phosphorus oxychloride in 25 mls of 1,2-dichloroethane.
`~ It is maintained for a further 3 hours under reflux.
After cooling to about 50C, one adds 250 mls of water and then one heats it again under a reflux for 45 minutes. After cooling :.
and decanting one extracts the organic phase with 50 mls of water; the aqueous phases are combined and heated to 50C. One .:

:- .

:

then adds a solution of 10.25 g of sodium perchlorate in 50 mls of distilled water. A precipitate is formed. After cooling for 30 minutes the precipitate is separated by filtration and dried. It is filtered and in this way one obtains 12.2 g of methylene-9,10-dioxy-1,2,3,4,6,7,12H-hexahydro(2,3~a) indolo-i quinolizinium perchlorate in the form of dark green crystals.
This perchlorate is dissolved under an atmosphere of nitrogen under a reflux in a mixture of 750 mls of methanol and 500 mls of water. It is cooled to 45C and then one adds 10 25 mls of 4N soda. A precipitate is formed. This mixture is cooled in an ice bath for 2 hours. The precipitate is separated by filtration and then dried. In this way one obtains 8.5 g of methylene-9,10-dioxy-2,3,4,6,7,12-hexahydro(2,3-a) indolo-; quinolizine in the form of a green solid melting at about 180C.
l-C2(methylene-5,6-dioxy-3-indolyl) ethyl~-2-piperidone may be prepared in the following manner:
One heats under a reflux a solution of 22 g of ~ methylene-3,4-dioxyphenylhydrazine hydrochloride in 880 mls of i -a mixture of ethanol and water (50:50 by volume) and 200 mls of j 20 5N hydrochloric acid. One then adds over a period of 5 minutes r ~i a solution of 28.4 g of 1-(4,4-diethoxybutyl)-2-piperidone in ¦ 140 mls of ethanol, heats it again under a reflux for 5 minutes.
~j After cooling, the solution is neutralised by the addition of 100 mls of a saturated solution of potassium bicarbonate. It is then extracted successively with 500, 350 and 350 mls of ` methylene chloride. The organic phases are combined, washed with 200 mls of water, dried over sodium sulphate, filtered over ; bleaching charcoal and evaporated to dryness under reduced pressure (20 mm of mercury). The residue (34 g) is chromato-graphed over 500 g of silica contained in a column with a '.~.
diameter of 5 cm, collecting fractions of 500 mls and eluting with ethyl acetate. Fractions 11 to 18 are combined and evaporated. In this way one obtains 11.75 g of 1- C2(methylene-5,6-dioxy-3-indolyl)ethy~ -2-piperidone melting at 180C.

One heats to 65C a solution of 7.3 g of 9,lQ-dimethoxy-2,3,4,6,7,12-hexahydro (2,3-a) indolo-quinolizine in 730 mls of -ethanol. One adds, over a period of 1 minute, 14.4 mls of a 30~ aqueous solution of formaldehyde. It is then left at 65C
for 10 minutes and then one adds in a single go 3.8 mls of 70~ perchloric acid. After cooling to 20C, one adds in small portions 4.9 g of sodium borohydride and then leaves it with agitation for 30 minutes. One adds 300 mls of a saturated solution of sodium chloride and 600 mls of methylene chloride.
After decanting, the aqueous phase is extracted with 300 mls of methylene chloride. The organic phases are combined, washed twice with 500 mls of water, dried over magnesium sulphate and :
evaporated to dryness under reduced pressure (20 mm of mercury).

;~ The residue (8.3 g) is chromatographed over 350 g of basic alumina contained in a column of 3.8 cm diameter, collecting ::
~ fractions of 300 mls and eluting with methylene chloride.
;.~.i Fractions 6 to 14 are combined and evaporated to dryness. The residue (5 g) recrystallised from 100 mls of ethyl acetate. One obtains in this way 3.5 g of 1,12b-trans-9,10-dimethoxy-1,12-methanoxymethano-l,2,3,4,6,7,12,12b-octahydro(2,3-a) indolo-quinolizine in the form of yellow crystals melting at 170C.
Analysis Calculated: C 69.49 H 7.37 N 8.53 O 14.61 Found: 69.0 6.8 8.4 14.9 9,10-dimethoxy-2,3,4,6,7,12-hexahydro (2,3-a) indolo-quinolizine may be prepared in the following manner:

One heats under a reflux for 3 hours a solution of 14 g of l-C2(5,6-dimethoxy-3-indolyl)ethyl~-2-piperidone and 11.7 mls of phosphorus oxychloride in 700 mls of 1,2-dichloroethane.
After cooling to 50C, one adds 350 mls of water and heats for 45 minutes under a reflux. After cooling and decanting, the organic phase is extracted twice with 50 mls of water. The -combined aqueous phases are heated to 50C; one then adds a lukewarm solution of 14 g of sodium perchlorate in 70 mls of water. A precipitate is formed. The suspension is cooled for 1 hour in an ice bath. The crystals are separated by filtration and dried. One obtains 13.7 g of 9,10-dimethoxy-1,2,3,4,6,7,12H-hexahydro (2,3-a) indolo-quinolizinium perchlorate in the form of green crystals.
This perchlorate (13.5 g) is dissolved under a reflux in a mixture of water and methanol (50:50 by volume). After cooling to 50C one adds, drop by drop, 10N soda so as to bring :.
the pH to 10. A precipitate is formed. The suspension is maintained for 1 hour in an ice bath and then the precipitate is separated by filtration and dried. One obtains in this way 7.4 g of 9,10-dimethoxy-2,3,4,6,7,12-hexahydro (2,3-a) indolo-`~ quinolizine in the form of a yellow solid melting at 122C.
1- ~2(5,6-dimethoxy-3-indolyl)ethy~ -2-piperidone may be prepared in the following manner:
One dissolves 54 g of 3,4-dimethoxy phenylhydrazine hydrochloride in a mixture of 750 mls of ethanol, 750 mls of . .
water and 350 mls of 5% hydrochloric acid. It is heated under a reflux, and then one adds over a period of 5 minutes a solution of 63 g of 1-(4,4-diethoxybutyl)-2-piperidone in 250 mls of ethanol. After heating under a reflux for 2 hours and then cooling, one eliminates the ethanol by distillation under reduced pressure (20 mm of mercury) and then extracts 7~3376 successively with 500 mls, 300 mls and 200 mls of methylene chloride. The combined organic phases are washed with 500 mls of water and then 500 mls of a saturated solution of sodium bicarbonate, dried over magnesium sulphate and evaporated to dryness under reduced pressure (20 mm of mercury). The residue (58 g) is chromatographed over 1 kg of silica gel contained in a column with a diameter of 6 cm, collecting fractions of 500 mls and eluting with ethyl acetate containing 1.5~ of methanol.
Fractions 31 to 43 are combined and evaporatad to dryness.
In this way one obtains 17 g of 1- C2(5,6-dimethoxy-3-indolyl) ethyl~-2-piperidone in the form of a thick yellow oil which slowly crystallises.
:

, One heats 570 mls of ethanol to 60C and then one 'A~ adds 5.85 g of 10-chloro-2,3,4,6,7,12-hexahydro ~2,3-a)-indolo-quinolizine.
One obtains a homogeneous solution to which one adds in one go 15.2 mls of 30% aqueous formaldehyde solution.
The reaction mixture is maintained for 10 minutes at 60C and then one adds over a period of one minute 3.85 mls of a 70~ aqueous solution of perchloric acid. After cooling to 20C, one adds with agitation, in small portions over a period of 15 minutes, 4.9 g of sodium borohydride. The excess of borohydride is destroyed by the addition of 290 mls of a 1.25 M
aqueous solution of sodium chloride. The agitation is continued for 20 minutes and then one extracts twice with 500 mls of dichloromethane.
The combined organic phases are washed with twice 200 mls of a 5 M sodium chloride solution and then dried over magnesium sulphate in the presence of bleaching charcoal, :

filtered, then concentrated to dryness under reduced pressure.
The product obtained (6.8 g) is agitated in a mixture of 20 mls of methanol and 40 mls of di-isopropyl oxide at 20C.
By filtration one obtains 4.0 g of a pale yellow crystalline powder melting at 207C, which is chromatographed over a column of 30 g of silica gel contained in a column of ; 2 cms in diameter, collecting fractions of 30 mls and eluting with a mixture of dichloromethane/methanol (97:3 by volume).
Fractions 3 to 8 are combined and evaporated.
The residue of 2.93 g is recrystallised from 600 mls of di-isopropyl oxide.
One obtains in this way 1.9 g of 1,12b-trans-10-chloro-1,12-methanoxymethano-1,2,3,4,6,7,12,12b-octahydro-(2,3-a)-indolo-quinolizine in the form of fine white needles melting at 209C.
Analysis: Calculated: O% 67.43, H% 6.33; Cl~ 11.71; N% 9.25;
O% 5.28 Found: C% 66.4; H% 6.4; Cl~ 11.7; N% 9.5;
~ i . .
, O% 5.5.
. 1 10-chloro-2,3,4,6,7,12-hexahydro-(2,3-a)-indolo-quinolizine may be prepared in the following manner:
One brings into suspension 15 g of 1-C2(6-chloro-3-indolyl)-ethyl~-2-piperidone in 700 mls of toluene and over a period of 5 minutes one adds a solution of 14 mls of phosphorus 1 oxychloride in 50 mls of toluene.
¦ The reaction mixtu~e is then heated for 3 hours at 80C. One adds 325 mls of distilled water and continues the heating to 80C for a further one hour. After 16 hours at 4C, the crystals are separated by filtration.

One obtains in this way 14 g of 10~-chloro-1,2,3,4,6,7,-12H-hexahydro-(2,3-a)-indolo-quinolizinium chloride.

10~37~

The chloride thus obtained is dissolved in 1000 mls of distilled water at 35 C.
After cooling to 20C one adds, drop by drop, 60 mls of lN soda.
The yellow precipitate obtained is separated by filtration, washed with water until neutral and then dried.
One obtains in this way 11.2 g of 10-chloro-2,3,4,6,7,-l~-hexahydro-(2,3-a)-indolo-quinolizine in the form of a yellow amorphous powder, which is used without any subsequent purification.
2~6-chloro-3-indolyl)-ethyl~ -2-piperidone may be prepared in the following manner:
One heats under a reflux under an atmosphere of ''! nitrogen 22 g of 6-chloro-tryptamine in 500 mls of 2-methoxy-ethanol containing in suspension 12 g of anhydrous sodium carbonate.
Whilst maintaining the agitation and the heating under a reflux one adds over a period of 48 hours a solution of 23.65 g -',Jj of ethyl 5-bromovalerianate in 200 mls of 2-methoxy-ethanol.
When the addition is completed, one maintains the 'l agitation and the heating under a reflux for a further 15 hours.
After cooling to 20C the mineral salts are separated ` by filtration and the filtrate is concentrated to dryness under ` reduced pressure (15 mm of mercury). One obtains a brown oil to which one adds 500 mls of water. It is acidified to a pH of 1 by the addition of 4N hydrochloric acid and then one extracts 4 times with 500 mls of dichloromethane.
The combined organic phases are washed with twice 500 mls of N hydrochloric acid, 4 times 500 mls of distilled water, and then dried over magnesium sulphate and finally concentrated to dryness under reduced pressure.

107837~

One obtains 31.5 g of a brown oil which is chromato-graphed over a column of 150 g of silica gel contained in a column with a diameter of 3.5 cms, collecting fractions of 1000 mls and eluting with a mixture of ethyl acetate and cyclohexane (35-65 by volume). Fractions 4 to 19 are combined and concentrated to dryness.
The residue of 22.5 g is recrystallised from ethyl acetate.
One obtains in this way 20.5 g of 1- ~2(6-chloro-3-' 10 indolyl)-ethy~ -2-piperidone in the form of fine white needles ~
, which melt at 188C. '
6-chloro-tryptamine may be prepared according to F. BENINGTON et al., J. Org. Chem., 25, 1542 (1960).

~ EXAMPLE 13 ;' One heats 1800 mls of ethanol to 60C and then one adds 18 g of 1~-methy1-2,3,4,6,7,12-hexahydro-(2,3-a)-indolo-uinolizine.
' ,, One obtai,ns a homogeneous solution to which one adds ' 44.S mls of 30% aqueous formaldehyde solution.
:, .
~' -- 20 One maintains the reaction mixture agitated for 10 minutes at 60C and then one adds in a single go 11.2 mls of '~ 70% perchloric acid and cools immediately by means of a water-bath.
As soon as the temperature of the mixture reaches 21C one adds, in small portions, over a period of 15 minutes, 1~ g of sodium borohydride. The agitation is continued for 30 minutes and then one adds 800 mls of a 2.5 M sodium chloride solution and one agitates for 45 minutes until gas ceases to be evolved.
One then extracts with twice 400 mls of dichloromethane.

~ 1078-37~; , The combined oxganic phases are washed with twice 200 mls of water and then dried over magnesium sulphate, bleached over bleaching charcoal, filtered and finally concen-trated to dryness. -One obtains 19 g of brown powder which is taken up again in 350 mls of acetone under a reflux.
It is allowed to crystallise by cooling to 0 C for one hour.
One obtains 7.5 g of yellow crystals.
By concentrating the filtrate to a small volume one obtains a second batch of 1.4 g under the same conditions.
The two batches are combined and chromatographed over a column of 117 g of silica gel contained in a column with a diameter of 3 cms, collecting fractions of 300 mls and eluting with dichloromethane.
Fractions 3 to 11 are combined and evaporated.
The residue of 6.4 g is recrystallised from 240 mls of acetone under a reflux.
One obtains in this way 6 g of 1,12b-trans-10-methyl-1,12-methanoxymethano-1,2,3,4,6,7,12,12b-octahydro-(2,3-a)-indolo-quinolizine in the form of fine white needles which melt at 178C.
Analysis: Calculated: C% 76.56; H~ 7.85; N% 9.92; O% 5.67 Found: C% 75.6; H% 8.0; N% 9.9; O% 5.9 10-methyl-2,3,4,6,7,12-hexahydro-(2,3-a)-indolo-quinolizine may be prepared in the following manner:
25 g of 1- r2(6-methyl-3-indolyl)-et~yl] -2-piperidone are suspended in 1200 mls of toluene and over a period of 5 minutes one adds a solution of 25.3 mls of phosphorus oxychloride in 50 mls of toluene.

~078376 The reaction mixture is heated at 80 C for 3 hours.
One adds 600 mls of distilled water and continues the heating at 80C for a further one hour.
One cools to a temperature in the vicinity of 20C ~ -and then one adds a solution of 21 g of sodium perchlorate monohydrate in 270 mls of water.
After 16 hours at a temperature in the vicinity of 4C, the crystals are separated by filtration, washed with water and dried.
One obtains in this way 44.8 g of wet product containing 31 g of 10-methyl-1,2,3,4,6,7,12H-hexahydro-(2,3-a)-indolo-quinolizinium perchlorate.
The wet perchlorate is dissolved in 2 litres of methanol under a reflux. One adds 2 litres of distilled water and maintains the heating under a reflux.
It is then allowed to return to a temperature in the vicinity of 20C. One obtains a clear yellow solution to which one adds 120 mls of 1 N soda, whilst agitating vigorously.
After 30 minutes' agitation the solid product is separated by filtration and washed with water to neutrality.
After drying one obtains 18.8 g of 10-methyl-2,3,4,6,7-12-hexahydro-(2,3-a)-indolo-quinolizine in the form of a light yellow powder which is used without subse~uent purification.
1- [2(6-methyl-3-indolyl)-ethy~ -2-piperidone may be prepared in the following manner:
One heats under a reflux under an atmosphere of nitrogen 21 g of 6-methyl-tryptamine in 500 mls of methoxyethanol containing 12.84 g of anhydrous sodium carbonate in suspension.
Whilst maintaining the agitation and the heating under a reflux one adds over a period of 20 hours a solution of 25.3 ?'11 .,',~
~' j; 107837 !~,' !
g of ethyl 5-bromovalerianate in 130 mls of 2-methoxyethanol.
When the addition is completed, one maintains the agitation and the heating under a reflux for 15 hours.
It is then flltered at 20C and the filtrate is concentrated under reduced pressure (15 mm of mercury).
One obtains a brown oil to which one adds 400 mls of water. It is acidified by the addition of 20 mls of 4 N
hydrochloric acid and extracted 4 times with 400 mls of dichloro-methane. The combined organic phases are washed successively with twice 500 mls of N hydrochloric acid and 4 times 500 mls distilled water, then dried over magnesium sulphate and finally concentrated to dryness under reduced pressure.
One obtains 28.8 g of a brown oil which is chromato-graphed over 140 g of silica contained in a column with a diameter of 3.5 cms, collecting fractions of 500 mls and eluting with an ethyl acetate gradient in cyclohexane.
Fractions 14 to 50 eluted with a mixture of ethyl acetate/cyclohexane (1:1 by volume) are combined and concen-trated to dryness under reduced pressure.
In this way one obtains 24.7 g of a solid melting at 140C which is recrystallised from 400 mls of ethyl acetate.
One obtains 23 g of 1-~2(6-methyl-3-indolyl)-ethy~ -2-piperidone in the form of fine silky needles melting at 154C and then 160C.
6-methyltryptamine may be prepared according to J.H. GASSUM et al, Quat. J. Exp. Physiol., 40, 49 (1955).

One dissolves 1.5 g of the product obtained in Example 1 in the form of a base in 200 mls of hot methanol.
One then adds 1.13 g of (l)-di-O,O'-paratoluoyl tartaric acid in i 1078376 ~ ' 20 mls of hot methanol. After standing for 14 hours at a temperature in the vicinity of 20C, the salt is separated by filtration and then recrystallised from 400 mls of a mixture of dioxan/methanol (75:25 by volume). After 14 hours standing at a temperature in the vicinity of 20C one obtains 1.36 g of salt which, after alkalisation and extraction provides 0.57 g of base, which is purified by chromatography over 15 g of silica in chloroform, eluting with a mixture of chloroform/methanol t98:2 by volume).
One obtains in this way 0.47 g of (1)-1,12b-trans-1,2,3,4,6,7,12,12b-octahydro-1,12-methanoxymethano-(2,3-a)-indolo-quinolizine:

(~)D = -127 (c = 1, chloroform) Operating as in Example 14 but starting off from 1.42 g of base and 1.07 g of (d)-di-O,O'-paratoluoyl tartaric acid, one obtains 0.355 g of (d)-1,12b-trans-1,2,3,4,6,7,12,12b-octa-hydro-1,12-methanoxymethano-(2,3-a)-indolo-quinolizine:

(~)D = + 124 (c = 1, chloroform) The pharmaceutical compositions containing a product of the general formula (I) and/or one of its salts in the pure state or in the presence of a diluent or of a casing constitute another object of the present invention. These compositions may be used per os, rectally or parenterally.
As solid compositions for oral administration one may use tablets, pills, powders or granules. In these compositions, the active product according to the invention is mixed with one or more inert diluents such as saccharose, lactose or starch.
These compositions may also include substances other than diluents, for example, wetting agents, swee~ening agents or 107837~i flavourings.
The compositions according to the invention forparenteral administration may be aqueous or non-aqueous sterile `
solutions, suspensions or emulsions. As solvent or vehicle one may use propyleneglycol, polyethyleneglycol, vegetable oils, particularly olive oil, injectable organic esters, for example ethyl oleate. These compositions may also contain adjuvants, particularly wetting agents, emulsifiers or dispersants. The sterilisation may be carried out in a number of ways, for example ~
by means of a bacteriological filter, incorporating sterilising -~ ;
agents in the composition, by irradiation or by heating. They ; may also be prepared in the form of sterile solid compositions which can be dissolved at the moment of use in sterile water or any other injectable sterile medium.
The compositions for rectal administration are suppositories which may contain, in addition to the active product, excipients such as cocoa butter or suppository wax.
In human therapy, the compositions according to the invention are particularly useful in the treatment of cerebro-vascular accidents and functional disorders of cerebralcirculatory insufficiency, in the treatment of arteriopathies of the limbs and circulatory troubles of the extremities.
The doses to be used depend on the effect aimed at and the duration of the treatment. They are generally between 25 and 500 mg per day by oral route for an adult, by intramuscular route they may be between 20 and 50 mg per day and by intravenous route, in slow perfusion, they may be between 10 and 30 mg per day.
Generally speaking, the physician will determine the 3~ dosage which he deems most appropriate, according to the age, `` 1078376 ':
weight and all the other factors connected with the patient to : be treated.

One prepares according to the usual technique tablets containing 25 mg of active product having the following composition:
- 1,12b-trans-1,2,3,4,6,7,12,12b-octahydro-1,12-methanooxymethano-2,3-a-indolo-quinolizine 0.025 g - starch 0.090 g 10 - precipitated silica 0.030 g - magnesium stearate 0.005 g

Claims (5)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A process for the preparation of pentacyclic deriva-tives of the general formula:

I

in which:
R represents a hydrogen atom or hydroxymethyl radical;
R1 represents a hydrogen atom;
R and R1 being in the trans position in relation to one another or alternatively together forming a double bond;
and R2 and R3, which may be the same or different, represent a hydrogen atom or a halogen atom or an alkyl radical containing 1 to 4 carbon atoms or alkloxyl radical whose alkyl part contains 1 to 4 carbon atoms or alternatively R2 and R3 together form a dioxmethylene radical, its optically active forms, its pharmaceuti-cally acceptable addition salts with acids, its pharmaceutically acceptable quaternary ammonium salts and its N-oxides;
which comprises reducing, in an acid medium an immonium salt of the general formula:

X- II

in which R, R2 and R3 are as defined above and X- represents an anion from an organic or inorganic acid;
or which comprises deprotonising, in an alkaline medium, a pro-duct of the general formula X- II

in which R2, R3 and X- are as defined above.
2. The compounds of general formula I when produced by the process of claim 1.
3. 1, 12b-trans-1,2,3,4,6,7,12,12b-octahydro-1,12-methano-oxymethano [2,3-a]-indolo-quinolizine, its pharmaceutical-ly acceptable salts and its optically active forms when produced by the process of claim 1.
4. A process in accordance with claim 1, wherein the reduction is carried out by means of alkali borohydride at a pH
in the vicinity of 6.
5. A process in accordance with claims 1 and 4 wherein the compound of the formula II is prepared by reacting formalde-hyde with a compound of the formula III:

III
in which R2 and R3 are as defined in claim 1 and the saltification of the product is obtained by means of an acid.
CA255,310A 1976-06-21 1976-06-21 Pentacyclic indolo-quinolizine derivatives Expired CA1078376A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA255,310A CA1078376A (en) 1976-06-21 1976-06-21 Pentacyclic indolo-quinolizine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA255,310A CA1078376A (en) 1976-06-21 1976-06-21 Pentacyclic indolo-quinolizine derivatives

Publications (1)

Publication Number Publication Date
CA1078376A true CA1078376A (en) 1980-05-27

Family

ID=4106248

Family Applications (1)

Application Number Title Priority Date Filing Date
CA255,310A Expired CA1078376A (en) 1976-06-21 1976-06-21 Pentacyclic indolo-quinolizine derivatives

Country Status (1)

Country Link
CA (1) CA1078376A (en)

Similar Documents

Publication Publication Date Title
CA3016182C (en) Substituted indole mcl-1 inhibitors
US5169947A (en) 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US8716319B2 (en) Substituted heterocyclic compounds
EP0091241B1 (en) Condensed pyrrolinone derivatives, and their production
CA2710234C (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
FI96690C (en) A process for preparing a therapeutically active benzopyridopiperidine, piperidylidene and piperazine compound
EP0258755B1 (en) Alpha-alkyl-4-amino-3-quinoline-methanols and 1-(4-aralkylamino-3-quinolinyl) alkanones, a process for their preparation and their use as medicaments
JPS61293984A (en) Active compound and its production and pharmaceutical composition containing the same
CN101305005A (en) Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases
CN109689639A (en) Spirolactams as ROCK inhibitor
CN111148740B (en) Compounds useful as autophagy modulators, methods of preparation and uses thereof
CA2104883A1 (en) Thienyl or pyrrolyl carboxylic derivatives; process for preparing the same and drugs containing them
RU2190612C2 (en) Novel derivatives of indole-2,3-dione-3-oxime
EP0337547A1 (en) Spirocyclic compounds incorporating five-membered rings with two heteroatoms
CA1271751A (en) Dihydroimidazo[1,2-a]pyrimidine derivatives
US20090181986A1 (en) Substituted heterocyclic compounds
WO1995007893A1 (en) Fused tricyclic heteroaromatic derivatives as dopamine receptor subtype ligands
US4138489A (en) Vasodilating octahydro-1,12-methano-oxymethano[2,3-a]-indoloquinolizines
US4753950A (en) Fused heterocyclic tetrahydroaminoquinolinols and related compounds
JPH07505394A (en) Bridged bisaryl carbinol derivatives, compositions and uses
TWI801378B (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
CA1078376A (en) Pentacyclic indolo-quinolizine derivatives
CN109311908A (en) Pyrazoline azatropylidene class compound as Akt inhibitor
JPH0733744A (en) Imidazole derivative and its salt
KR0128975B1 (en) 9-acylamino-tetrahydroacridine derivatives and memory euhancing agent containing said derivative as active ingredient

Legal Events

Date Code Title Description
MKEX Expiry